Accompanying research of Phase II study of nivolumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy

Accompanying research of Phase II study of nivolumab for advanced non-small-cell lung cancer patients not indicative of cytotoxic chemotherapy - 1693-A

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000025306

Enrollment

Registered

2016-12-17

Start date

2016-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients enrolled onto the Phase II safety and efficacy study of nivolumab in poor performance status patients with previously treated advanced NSCLC (UMIN000020855) 2) Patients providing written informed consent.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To explore the relationship between immunological state of nivolumab treated patients having NSCLC with poor performance status	—

Countries

Japan

Contacts

Public ContactYusuke Okuma

Tokyo Metropolitan Cancer and Infectious disease Center Komagome Hospital Department of Respiratory Medicine and Thoracic Oncology

y-okuma@cick.jp03-3823-2101

Outcome results